Cogent Biosciences Inc. (COGT) Prepares for Bezuclastinib Introduction, Awaiting FDA Approval
Cogent Biosciences Inc. is poised for the launch of its innovative drug, bezuclastinib, following a strong start to 2026 marked by significant regulatory advancements. The US FDA has accepted the company's New Drug Application for bezuclastinib to treat Gastrointestinal Stromal Tumors, a decision supported by its Breakthrough Therapy Designation. Clinical trials have demonstrated clear benefits, and the company anticipates a market debut in the latter half of 2026, pending final FDA approval. This development highlights Cogent's dedication to advancing precision therapies.






